The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (interstitial lung disease/ILD)
Publications
Severe interstitial lung disease following treatment with certolizumab pegol: a case report.
European respiratory review : an official journal of the European Respiratory Society. 2013;22(129):414-6
A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis.
Rheumatology (Oxford, England). 2013;52(12):2302-4
Interstitial lung disease following certolizumab pegol.
Rheumatology (Oxford, England). 2012;51(3):578-80